Biogen
Q2 2023 Earnings Call
Jul 25, 2023, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good morning. My name is Ruth, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen's second-quarter 2023 earnings call and business update. All lines have been placed on mute to prevent any background noise.
After the speakers' remarks, there will be a question-and-answer session. [Operator's instructions] Today's conference is being recorded. At this time, I would now like to turn the conference over to Mr. Chuck Triano, head of investor relations.
Mr. Triano, you may begin your conference.
Chuck Triano -- Head of Investor Relations
Thank you, operator. Good morning and welcome to Biogen's second-quarter 2023 earnings call. Before we begin, I encourage everyone to go to the Investors section of biogen.com to find the earnings release and related financial tables, including our GAAP financial measures and a reconciliation of the GAAP to non-GAAP financial measures that we will discuss today. Our GAAP financials are provided in Tables 1 and 2, and Table 4 includes a reconciliation of our GAAP to non-GAAP financial results.
We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We have also posted slides on our website that will follow the discussion related to this call. I would like to point out that we will be making forward-looking statements which are based on our expectation. These statements are subject to certain risks and uncertainties and our actual results may differ materially.
I encourage you to consult the risk factors discussed in our SEC filings for additional detail. On today's call, I'm joined by our president and chief executive officer, Chris Viehbacher; Dr. Priya Singhal, head of development; and our CFO, Mike McDonnell. Chris, Priya, and Mike will each make some opening comments, and then we'll move to the Q&A session. To allow us to get through as many questions as possible, we kindly ask that you limit yourself to one question.
I'll now turn the call over to Chris.
Christopher Viehbacher -- President and Chief Executive Officer
Thank you, Chuck. Good morning, everybody. I'd like to start off with Leqembi. And, you know, I think before we really get into all the interesting details of commercialization and competitiveness, just like to pause for a moment.